ABSTRACT
Objective To establish the importance of evaluating ultrasensitive C-reactive protein (us-CRP) in a pediatric group with obesity as the main biomarker, detecting, as early as possible, cardiometabolic complications.
Methods This is a control-case, cross-sectional study involving the biochemical and anthropometric evaluation of 342 children and adolescents participating in the Preventive Medicine Service, in Aracaju, Sergipe, Brazil. When evaluated anthropometrically, it was observed that, in 235 of the cases, the body mass index (BMI) above the 97th percentile or the Z-score greater than +2 allowed their classification as obese. The control group consisted of 107 non-obese individuals. The sample was divided into three age groups according to the International Diabetes Federation (FID): 6–10 years, 10–16 years and >16 years, representing 45%, 39% and 14% of the sample population, respectively.
Results The CRP-us showed an average value of 2.36 ± 1.28 mg/dL in the obese group, while in the control group, the result found was 0.01 ± 0.1 mg/dL. There was a significant correlation between the increase in CRP levels in the obese group and other biochemical and anthropometric findings in the same group, such as: reduced HDL, elevated triglycerides, higher BMI, and increased abdominal circumference (AC). Homocysteine, in turn, proved to be a biomarker with little specificity in the sample in question.
Conclusion The ultra-sensitive C-reactive protein, already fundamentally correlated with increased cardiovascular risk in adults, demonstrates to be a validated biomarker, showing high sensitivity even in pediatric obese populations.
Objetivo Estabelecer a importância da avaliação da proteína C reativa ultrassensível (PCR-us) como principal biomarcador em um grupo pediátrico com obesidade, detectando precocemente possíveis complicações cardiometabólicas.
Métodos Trata-se de um estudo caso-controle, transversal envolvendo avaliação bioquímica e antropométrica de 342 crianças e adolescentes, participantes do Serviço de Medicina Preventiva, em Aracaju-Sergipe, Brasil. Quando avaliados antropometricamente, observou-se que em 235 participantes o IMC acima do percentil 97 ou o Z-escore maior que +2 permitia classificá-los como obesos. O grupo controle consistiu de 107 indivíduos não obesos. A amostra foi dividida em três faixas etárias de acordo com a Federação Internacional de Diabetes (FID): 6–10 anos, 10–16 anos e > 16 anos, representando, respectivamente, 45%, 39% e 14% da população amostral.
Resultados A PCR-us apresentou um valor médio de 2.36 ± 1.28 mg/dL no grupo obeso, enquanto no grupo controle o resultado encontrado foi de 0.01 ± 0.1 mg/dL. Observou-se uma correlação significativa do aumento dos níveis de PCR-us no grupo obeso com outros achados bioquímicos e antropométricos do mesmo conjunto, como: redução do HDL, elevação de triglicérides, maior grau de IMC e aumento da CA. A homocisteína, por sua vez, demonstrou ser um biomarcador com pouca especificidade na amostra em questão.
Conclusão A proteína C reativa ultrassensível, já fundamentadamente correlacionada ao aumento do risco cardiovascular em adultos, demonstra ser um validado biomarcador, apresentando alta sensibilidade mesmo em populações pediátricas obesas.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Committee of the State University of Santa Cruz, under the presentation of Certificate for Ethics Assessment 04065412.600005526 of Platform Brazil.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The entire data set that supports the results of this study was published in the article itself.
